niacinamide has been researched along with digitoxin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fujimoto, JM; Smith, DS | 1 |
| Chen, PC; Guo, L; Huang, Y; Kwok, HF; Li, B; Li, L; Lin, Y; Meng, C; Neves, H; Xiao, Y; Yan, W | 1 |
3 other study(ies) available for niacinamide and digitoxin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Alterations produced by novobiocin during biliary excretion of morphine, morphine-3-glucuronide and other compounds.
Topics: Analysis of Variance; Animals; Bile; Bilirubin; Carbon Radioisotopes; Digitoxin; Glucuronates; Liver; Male; Mannitol; Morphine; Niacinamide; Novobiocin; Ouabain; Procainamide; Rats; Sulfobromophthalein; Time Factors; Tritium; Tubocurarine | 1974 |
Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cardiotonic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Digitoxin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2017 |